rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MacroGenics, Inc.

MGNX · Nasdaq

Health CareBiotechnologyNot moving yet

MGNX stood above a rising 150-day average in 38 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 15.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$258K
Officials’ trades on record
0
Institutions holding
121 (+17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 38 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$243K$0$136KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Jeffrey Stuart PetersSenior VP, GC, and Secretarysold31,105at $4.1519 Aug 2026filed 20 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders121+17 on the quarter
New · exited39 · 23
Reported value$214.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 20265,006,752$23.1M-1,005,248−16.7%
BlackRock, Inc.added · filed 7 Aug 20264,679,229$21.6M+3,516,083+302.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,656,010$12.3M+2,157+0.1%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20262,632,750$12.2M-330,809−11.2%
BANK OF AMERICA CORPadded · filed 14 Aug 20262,488,252$11.5M+86,438+3.6%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 20262,465,699$11.4M-62,130−2.5%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20262,374,296$11.0M-420,061−15.0%
WASATCH ADVISORS LPadded · filed 10 Jul 20262,018,881$9.3M+459,180+29.4%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20261,864,176$8.6M00.0%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,820,231$8.4M+611,456+50.6%
31 Mar 2023 – 30 Jun 2026
85115144Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Ezio Bonvini Company insiderSr VP, Research & CSO · last 6 Oct 20260 · 18
Jeffrey Stuart Peters Company insiderSenior VP, GC, and Secretary · last 19 Aug 20260 · 9
David C. Stump Company insiderDirector · last 19 May 20260 · 0
Edward Hurwitz Company insiderDirector · last 19 May 20261 · 1
Federica F. O'Brien Company insiderDirector · last 19 May 20260 · 0
Karen Jean Ferrante Company insiderDirector · last 19 May 20260 · 0
Margaret Liu Company insiderDirector · last 19 May 20260 · 0
Meenu Chhabra Company insiderDirector · last 19 May 20260 · 0
Scott Koenig Company insiderDirector · last 19 May 20260 · 0
Scott Thomas Jackson Company insiderDirector · last 19 May 20260 · 0
William K. Heiden Company insiderDirector · last 19 May 20262 · 0
Jay Philip Siegel Company insiderDirector · last 18 May 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 2025100%
Operating profit marginFY 2025 · to 31 Dec 2025-48.7%
Free cash flow marginFY 2025 · to 31 Dec 2025-55.5%
Return on capital employedFY 2025 · to 31 Dec 2025-34.1%
Research spendFY 2025 · to 31 Dec 202598.4%
Share count trendFY 2025 · to 5 Mar 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$57.2M
Free cash flowFY 2025 · to 31 Dec 2025−$83.0M

Analyst forecasts

No analyst forecasts yet.